{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:39:13Z","timestamp":1793425153699,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ANCA-associated vasculitis (AAV) is a group of autoimmune diseases characterized by small vessel inflammation, diagnosed primarily through clinical features, histopathology, and ANCA testing. Novel biomarkers derived from routine blood counts, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), may support disease assessment. This study evaluated their utility in distinguishing AAV patients, reflecting disease activity, and predicting prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective case-control study, 65 AAV patients and 65 age- and sex-matched healthy controls were enrolled. AAV diagnosis adhered to the 2012 Chapel Hill Consensus and the American College of Rheumatology 1990 criteria. NLR, PLR, MLR, SII, and SIRI were calculated from complete blood counts. Disease activity (Birmingham Vasculitis Activity Score, BVAS), extent (Disease Extent Index, DEI), damage (Vasculitis Damage Index, VDI), and prognosis (Five-Factor Score, FFS 2009) were assessed. Statistical analyses included Mann-Whitney U tests, Spearman correlations, and receiver operating characteristic (ROC) curves to evaluate discriminatory and predictive capacities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      AAV patients exhibited significantly higher NLR (6.94 \u00b1 0.76 vs. 1.88 \u00b1 0.08), PLR (242.44 \u00b1 23.09 vs. 125.97 \u00b1 4.34), MLR (0.44 \u00b1 0.03 vs. 0.20 \u00b1 0.01), SII (1813.71 \u00b1 221.85 vs. 446.62 \u00b1 22.40), and SIRI (3.19 \u00b1 0.31 vs. 0.72 \u00b1 0.06) compared to controls (all P &amp;lt; 0.001). ROC analysis showed strong discriminatory power, with SIRI (AUC = 0.902) and NLR (AUC = 0.885) performing best. NLR, PLR, SII, and SIRI correlated positively with BVAS (rs = 0.325-0.356,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01) and FFS 2009 (rs = 0.358-0.386,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05), and all markers correlated with DEI (rs = 0.396-0.488,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01), but not VDI. For predicting active disease (BVAS \u2265 15), SII had the highest AUC (0.726,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NLR, PLR, MLR, SII, and SIRI effectively distinguish AAV patients from controls and reflect disease activity, extent, and prognosis. While not standalone diagnostic tools, these markers offer valuable support to standard AAV assessment, particularly in challenging cases. Their accessibility suggests potential for enhancing clinical management, pending validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1588287","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T01:28:35Z","timestamp":1750123715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The diagnostic and prognostic role of novel biomarkers in anti-neutrophil cytoplasmic antibody-associated vasculitis"],"prefix":"10.3389","volume":"16","author":[{"given":"Ruohan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-associated vasculitis","volume":"17","author":"Yates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203255","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group","volume":"72","author":"Millet","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2019.39.4.345","article-title":"The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases","volume":"39","author":"Gasparyan","year":"2019","journal-title":"Ann Lab Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"105342","DOI":"10.1016\/j.jbspin.2022.105342","article-title":"Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio reflect disease activity and flares in patients with systemic lupus erythematosus - A prospective study","volume":"89","author":"Cho","year":"2022","journal-title":"Joint Bone Spine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S460610","article-title":"The clinical value of the neutrophil-to-lymphocyte ratio, the C-reactive protein-to-albumin ratio, the systemic inflammatory index, and the systemic inflammatory response index in patients with the anti-synthetase syndrome","volume":"17","author":"Huang","year":"2024","journal-title":"J Inflammation Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12882-018-0992-4","article-title":"Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis in patients with ANCA-associated vasculitis: a retrospective study","volume":"19","author":"Ahn","year":"2018","journal-title":"BMC Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.855869","article-title":"Relationship between C-reactive protein\/serum albumin ratio, neutrophil\/lymphocyte ratio, and ANCA-associated vasculitis activity: A retrospective single center cohort study","volume":"9","author":"Tian","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s42358-019-0110-8","article-title":"Platelet\/lymphocyte ratio and mean platelet volume in patients with granulomatosis with polyangiitis","volume":"60","author":"Kucuk","year":"2019","journal-title":"Adv Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2021.07.005","article-title":"The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study","volume":"41","author":"Fonseca","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.300512","article-title":"Platelets as cellular effectors of inflammation in vascular diseases","volume":"112","author":"Rondina","year":"2013","journal-title":"Circ Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0560.2002.290309.x","article-title":"Platelet involvement in cutaneous small vessel vasculitis","volume":"29","author":"Meijer-Jorna","year":"2002","journal-title":"J Cutan Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13230","article-title":"Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease","volume":"50","author":"Yang","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1530534","article-title":"SIRI and SII as potential biomarkers of disease activity and lupus nephritis in systemic lupus erythematosus","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/apm.2017.125.issue-10","article-title":"Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases","volume":"125","author":"Yang","year":"2017","journal-title":"APMIS"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1588287\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T01:28:36Z","timestamp":1750123716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1588287\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2025.1588287"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1588287","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"article-number":"1588287"}}